Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 10, Octobre 2013
Page(s) 836 - 839
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20132910008
Publié en ligne 18 octobre 2013
  1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957 ; 147 : 258–267. [CrossRef] [PubMed] [Google Scholar]
  2. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008 ; 17 : 394–399. [CrossRef] [PubMed] [Google Scholar]
  3. Odorizzi PM, Wherry EJ. Immunology. An interferon paradox. Science 2013 ; 340 : 155–156. [CrossRef] [PubMed] [Google Scholar]
  4. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013 ; 340 : 207–211. [CrossRef] [PubMed] [Google Scholar]
  5. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013 ; 340 : 202–207. [CrossRef] [PubMed] [Google Scholar]
  6. Bolen CR, Robek MD, Brodsky L, et al. The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response. J Interferon Cytokine Res 2013 ; 33 : 15–23. [CrossRef] [PubMed] [Google Scholar]
  7. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008 ; 105 : 7034–7039. [CrossRef] [Google Scholar]
  8. Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1–infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol 1999 ; 20 : 358–370. [CrossRef] [PubMed] [Google Scholar]
  9. Sedaghat AR, German J, Teslovich TM, et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol 2008 ; 82 : 1870–1883. [CrossRef] [PubMed] [Google Scholar]
  10. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013 ; 65 : 1011–1021. [CrossRef] [PubMed] [Google Scholar]
  11. McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012 ; 64 : 3666–3676. [CrossRef] [PubMed] [Google Scholar]
  12. Tcherepanova I, Curtis M, Sale M, et al. Results of a randomized placebo controlled phase study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus. Berlin Annual European Congress on Rheumatology-EULAR, 2012. [Google Scholar]
  13. Wang B, Higgs BW, Chang L, et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody. Clin Pharmacol Ther 2013 ; 93 : 483–492. [CrossRef] [PubMed] [Google Scholar]
  14. Terrier B, Mouthon L. Lupus érythémateux systémique. Traitements par anticorps monoclonaux et molécules recombinantes. Med Sci (Paris) 2013 ; 29 : 65–73. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  15. Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2013 (sous presse). [Google Scholar]
  16. Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum 2013 ; 65 : 447–456. [CrossRef] [PubMed] [Google Scholar]
  17. Bensussan A, Bizzini B, Pouletty P, Gallo R, Zagury D. Les kinoïdes. Med Sci (Paris) 2008 ; 24 : 306–313. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.